




or

A²
Cont.


--3. (Amended) The method as defined in Claim 34 wherein the compound employed has the structure



--4. (Amended) The method as defined in Claim 34 wherein the compound employed has the structure



or



--5. (Amended) The method as defined in Claim 34 where in the compound employed (CH₂)_x is alkylene, alkenylene, allenyl, or alkynylene. --


--10. (Amended) The method as defined in Claim 34 where in the compound employed

A³


(CH₂)_x is CH₂, (CH₂)₂, (CH₂)₃, or $\begin{array}{c} \text{CH}_3 & \text{CH}_3 \\ & \diagdown \\ & \text{C} \\ & \diagup \\ & \text{CH}_3 \end{array}$, (CH₂)_m is CH₂, or $\begin{array}{c} \text{R}_a \\ | \\ \text{CH} \end{array}$ where R_a is alkyl or alkenyl, (CH₂)_n is CH₂, R¹ is lower alkyl, R² is H, R^{2a} is H, R⁴ is H, and R³ is arylalkyloxycarbonyl,



A3
CONT.
aryloxycarbonyl, haloaryl-oxycarbonyl, alkoxyaryloxycarbonyl, alkylaryloxycarbonyl, aryloxyaryloxycarbonyl, heteroaryloxyarylalkyl, heteroaryloxycarbonyl, arylalkenylloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, alkyloxyaryloxycarbonyl, arylalkylsulfonyl, arylalkenylsulfonyl, arylthiocarbonyl, cycloheteroalkylalkyloxycarbonyl, cycloheteroalkyloxycarbonyl, or polyhaloalkylaryloxycarbonyl, which may be optionally substituted. --

--14. (Amended) The method as defined in Claim 34 where the compound employed has the structure





--16. (Amended) The method as defined in Claim 34 wherein the compound employed has the structure












,







AS





CONT.








AS
unit-






AS





WT.













AS




cont.






15
cont.

















A5








Cont.











AS
cont.












AS
cont.













where $R^{3e} =$












Cont'd











AS
CONT.




where $R^{3g} =$











AS



com









, where $R^3 =$




AS

W.M.










AS








Cont'd








μ
cont.







AS

cont.










(±)



AS




Cont.










AS



Cont'd










AS
cont.


















AS
cont.

















AS
cont























--17. (Amended) The method as defined in Claim 34 wherein the compound employed
has the structure
















AS





Cont.




--18. (Amended) The method as defined in Claim 34 wherein the compound employed has the structure







AS
cont.





Sub
AS
cont.









--20. (Amended) The method as defined in Claim 34 wherein the compound employed has the structure























●







b
CON⁻





























A6

CMM

























Ab
cont









--21. (Amended) The method as defined in Claim 55 wherein the compound employed


has the structure




--22. (Amended) The method as defined in Claim 55 wherein the compound employed

has the structure




*cont.*


or




--26. (Amended) The method as defined in Claim 55 wherein the compound employed
has the structure




--27. (Amended) The method as defined in Claim 55 wherein the compound employed
has the structure




--28. (Amended) The method as defined in Claim 55 wherein the compound employed has the structure



--30. (Amended) The method as defined in Claim 55 wherein the compound employed has the structure




--31. (Amended) The method as defined in Claim 55 wherein the compound employed has the structure




A8
cont.

--32. (Amended) The method as defined in Claim 55 wherein the compound employed has the structure



--34. (Amended) A method for lowering blood glucose levels or for treating diabetes, or for treating a premalignant disease, an early malignant disease, a malignant disease, or a dysplastic disease, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound which has the structure



wherein x is 1, 2, 3 or 4; m is 1 or 2; n is 1 or 2;

Q is C or N;

A is O or S;

Z is O or a bond;

R¹ is H or lower alkyl;

X is CH;

R² is H, alkyl, alkoxy, halogen, amino or substituted amino;

R^{2a}, R^{2b} and R^{2c} are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

R³ is aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, alkyl(halo)aryloxycarbonyl, alkyloxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxy carbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxycarbonyl, arylalkyloxycarbonyl, alkylaryloxycarbonyl,


A9

alkynyoxy carbonyl, haloalkoxy aryloxy carbonyl, alkoxy carbonyl aryloxy carbonyl, aryloxy aryloxy carbonyl, arylalkenyoxy carbonyl, heteroaryloxy arylalkyl, aryloxy arylalkyloxy carbonyl, aryloxy alkyl carbonyl, arylalkylsulfonyl, arylthiocarbonyl, arylalkenylsulfonyl, heteroaryl sulfonyl, arylsulfonyl, heteroarylalkoxy carbonyl, heteroarylalkyloxy arylalkyl, arylalkenyl arylalkyl, arylalkoxy carbonyl heteroarylalkyl, heteroaryloxy arylalkyl, arylalkenyl heteroarylalkyl or polyhaloalkyl aryl oxy carbonyl;

C9M.

Y is CO_2R^4 where R^4 is H or alkyl, or a prodrug ester or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure $\text{P}(\text{O})(\text{OR}^{4a})\text{R}^5$ where R^{4a} is H or a prodrug ester, R^5 is alkyl or aryl or a phosphonic acid of the structure $\text{P}(\text{O})(\text{OR}^{4a})_2$ where R^{4a} is H or a prodrug ester; or stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof. --

--37.(Amended) A pharmaceutical combination comprising a compound which has the structure



wherein x is 1,2, 3 or 4; m is 1 or 2; n is 1 or 2;

Q is C or N;

A is O or S;

Z is O or a bond;

R^1 is H or lower alkyl;

X is CH;

R^2 is H, alkyl, alkoxy, halogen, amino or substituted amino;

R^{2a} , R^{2b} and R^{2c} are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

R^3 is aryloxycarbonyl, alkyloxycarbonyl, alkynyoxy carbonyl, alkenyloxycarbonyl, alkyl(halo)aryloxycarbonyl, alkyloxy(halo)aryloxycarbonyl, cycloalkyl aryl oxy carbonyl, cycloalkyloxy aryl oxy carbonyl, alkylcarbonylamino, arylcarbonylamino, heteroaryl carbonylamino, alkoxy carbonylamino, aryloxycarbonylamino, heteroaryloxy carbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxy carbonyl, cycloheteroalkyloxy carbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxy carbonyl, arylalkyloxy carbonyl, alkylaryloxy carbonyl,

A10
COM.
A11

alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxy carbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylalkenyloxycarbonyl, heteroaryloxyarylalkyl, aryloxyarylalkyloxycarbonyl, aryloxyalkyloxycarbonyl, arylalkylsulfonyl, arylthiocarbonyl, arylalkenylsulfonyl, heteroarylsulfonyl, arylsulfonyl, heteroarylalkoxycarbonyl, heteroarylalkyloxylalkyl, arylalkenylarylkyl, arylalkoxycarbonylheteroarylalkyl, heteroaryloxyarylalkyl, arylalkenylheteroarylalkyl or polyhaloalkylaryloxycarbonyl;

Y is CO_2R^4 where R^4 is H or alkyl, or a prodrug ester or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure $\text{P}(\text{O})(\text{OR}^{4a})\text{R}^5$ where R^{4a} is H or a prodrug ester, R^5 is alkyl or aryl or a phosphonic acid of the structure $\text{P}(\text{O})(\text{OR}^{4a})_2$ where R^{4a} is H or a prodrug ester;

or stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof, and a lipid-lowering agent, a lipid modulating agent, an antidiabetic agent, an anti-obesity agent, an antihypertensive agent, a platelet aggregation inhibitor, and/or an antiosteoporosis agent. --

--39. (Amended) The combination as defined in Claim 37 wherein the antidiabetic agent is 1, 2, 3 or more of a biguanide, a sulfonyl urea, a glucosidase inhibitor, a PPAR α agonist, a PPAR γ agonist, a PPAR α/γ dual agonist, an SGLT2 inhibitor, a DP4 inhibitor, an aP2 inhibitor, an insulin sensitizer, a glucagon-like peptide-I (GLP-I), insulin and/or a meglitinide; the anti-obesity agent is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor agonist, an aP2 inhibitor and/or an anorectic agent; the lipid lowering agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibrin acid derivative, an upregulator of LDL receptor activity, a lipoxygenase inhibitor, or an ACAT inhibitor; the antihypertensive agent is an ACE inhibitor, angiotensin II receptor antagonist, NEP/ACE inhibitor, calcium channel blocker and/or β -adrenergic blocker. --

--40. (Amended) The combination as defined in Claim 39 wherein the antidiabetic agent is 1, 2, 3 or more of metformin, glyburide, glimepiride, gliclazide, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, Gl-262570, isaglitazone, JTT-501, NN-2344, L895645, YM-440, R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-HO39242, GW-409544, KRP297, AC2993, LY315902, P32/98 and/or NVP-DPP-728A; the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol; the lipid lowering agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin,

A11
 itavastatin, visastatin, fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, cholestagel, niacin and/or LY295427; the antihypertensive agent is an ACE inhibitor which is captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril or moexipril; an NEP/ACE inhibitor which is omapatrilat, [S[(R*,R*)]-hexahydro-6-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid (gemopatrilat) or CGS 30440;


Cont.

an angiotensin II receptor antagonist which is irbesartan, losartan or valsartan; amlodipine besylate, prazosin HCl, verapamil, nifedipine, nadolol, propranolol, carvedilol, or clonidine HCl; the platelet aggregation inhibitor is aspirin, clopidogrel, ticlopidine, dipyridamole or ifetroban. --

A12
 --50. (Amended) A method for treating insulin resistance, hyperglycemia, hyperinsulinemia, or elevated blood levels of free fatty acids or glycerol, hyperlipidemia, obesity, Syndrome X, dysmetabolic syndrome, inflammation, diabetic complications, impaired glucose homeostasis, impaired glucose tolerance, hypertriglyceridemia, atherosclerosis, or for treating irritable bowel syndrome, Crohn's disease, gastric ulceritis or osteoporosis, or psoriasis, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a pharmaceutical combination as defined in Claim 37. --

A13
 Please add the following Claims 55 and 56.

55. A method for lowering blood glucose levels or for treating diabetes, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound which has the structure



where R¹ is alkyl,

(CH₂)_m is CH₂ or $\begin{array}{c} \text{CH}_3 \\ | \\ \text{---} \text{CH} \text{---} \end{array}$ and R³ is aryloxycarbonyl or alkoxyaryloxycarbonyl.